Success Metrics

Clinical Success Rate
95.0%

Based on 19 completed trials

Completion Rate
95%(19/20)
Active Trials
0(0%)
Results Posted
16%(3 trials)
Terminated
1(5%)

Phase Distribution

Ph phase_2
1
5%
Ph phase_1
19
90%
Ph phase_3
1
5%

Phase Distribution

19

Early Stage

1

Mid Stage

1

Late Stage

Phase Distribution21 total trials
Phase 1Safety & dosage
19(90.5%)
Phase 2Efficacy & side effects
1(4.8%)
Phase 3Large-scale testing
1(4.8%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

90.5%

19 of 21 finished

Non-Completion Rate

9.5%

2 ended early

Currently Active

0

trials recruiting

Total Trials

21

all time

Status Distribution
Completed(19)
Terminated(2)

Detailed Status

Completed19
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
21
Active
0
Success Rate
95.0%
Most Advanced
Phase 3

Trials by Phase

Phase 119 (90.5%)
Phase 21 (4.8%)
Phase 31 (4.8%)

Trials by Status

completed1990%
terminated15%
withdrawn15%

Recent Activity

Clinical Trials (21)

Showing 20 of 21 trialsScroll for more
NCT07214922Phase 1

Relative Bioavailability of Evobrutinib Tablet Batches

Completed
NCT06661694Phase 1

A Study to Learn How Different Tablets of the Study Medicine Mevrometostat Are Taken up Into the Blood in Healthy Adults

Withdrawn
NCT04489134Phase 2

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release

Completed
NCT05463497Phase 1

To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers

Completed
NCT04049175Phase 3

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma

Terminated
NCT04798222Phase 1

Study to Assess the Bioavailability of Different Formulations of AZD9977 and Dapagliflozin and Influence of Food in Selected Formulations in Healthy Volunteers

Completed
NCT03804645Phase 1

A Study to Assess the Reaction of Body for Four Different Formulations of AZD9977 (Part A) and Influence of Food and Lower Dose of a Selected Formulation (Part B) in Healthy Male Subjects

Completed
NCT03942666Phase 1

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Completed
NCT03441984Phase 1

To Assess the Relative Bioavailability (BA) of TRIUMEQ® and Dolutegravir and Lamivudine (DTG/3TC) Pediatric Dispersible Tablet Formulations in Healthy Volunteers

Completed
NCT03978143Phase 1

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

Completed
NCT01244035Phase 1

Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Completed
NCT01272375Phase 1

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Completed
NCT03649165Phase 1

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

Completed
NCT02385071Phase 1

A Crossover Study to Evaluate Relative Bioavailability of Simeprevir Age-appropriate Oral Formulation Candidates Compared With 150-milligram (mg) Oral Capsule in Healthy Adult Participants

Completed
NCT01897389Phase 1

A Study to Assess the Relative Bioavailability of 4 New Abiraterone Acetate Tablet Formulations With Respect to the Current Commercial Abiraterone Acetate Tablet Under Fasted Conditions in Healthy Male Participants

Completed
NCT02256735Phase 1

Study to Investigate the Effect of KUC 7483 CL on the QT/QTc Interval of the ECG in Comparison to Placebo and Moxifloxacin in Healthy Male and Female Volunteers

Completed
NCT01841489Phase 1

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Completed
NCT00946842Phase 1

A Study to Determine the Relative Oral Bioavailability of Single Dose Administration of TMC207, Under Fed and Fasted Conditions in Healthy Participants

Completed
NCT01181700Phase 1

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Completed
NCT01043276Phase 1

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

Completed

Drug Details

Intervention Type
DRUG
Total Trials
21